Overview of the Requirements on WFI in the EU, USA and Japan
Recommendation

Thursday, 12 February 2026 9 .00 - 17.00 h
Best Practice for Manual and Automated Visual Inspection of Parenterals
Again and again, the question arises about the limits laid down in the different GMP regulations and Pharmacopoeias and what procedures are applicable to the manufacture of water for injection (WFI). The table below gives you an overview of the current requirements on the production as well as on certain testing elements. It is remarkable to notice that only EU authorities are against the inclusion of membrane procedures for the production of WFI.
|
| USP | EP | JP |
| Production of WFI | Distillation or purification process proven to be equivalent or superior to distillation | Distillation only | Distillation or RO/UF |
| Conductivity [µS/cm at 25 °C or equivalent at other temperatures] | 1.3 | 1.3 | 1.3 |
| TOC [ppb] | ≤ 500 | ≤500 | ≤ 500 |
| Endotoxin | 0.25 EU/mL | 0.25 EU/mL | 0.25 EU/mL |
| Bacteria [cfu/100 mL] | 10 | 10 | 10 |
| Nitrates [ppm] | N/A | 0.2 | N/A |
| Ammonium [mg/L] | N/A | N/A | N/A |
Related GMP News
10.12.2025VDI 6022 Sheet 8.1 published: Qualification for the cleaning of air-conditioning systems
10.12.2025Typical GMP Deficiencies in the Area of Technology in FDA Inspections 2024/2025
03.12.2025Deficient Water System: Warning Letter from the FDA
26.11.2025Revised Container-/Closure-Integrity Testing (CCIT) Position Paper available
12.11.2025New VDI Guideline 2083 Sheet 22 published: Measurement of Condensable Airborne Substances


